Characterization of clonal immunoglobulin heavy V-D-J gene rearrangements in Chinese patients with chronic lymphocytic leukemia: Clinical features and molecular profiles
暂无分享,去创建一个
M. Xiao | Meilan Zhang | Jiachen Wang | Xiaoxi Zhou | Xinyu Deng | Min Xiao
[1] Chuan-Chao Wang,et al. Distinct Immunogenetic Profiles of Chronic Lymphocytic Leukemia in Asia: A Taiwan Cooperative Oncology Group Registry Study , 2022, HemaSphere.
[2] K. Stamatopoulos,et al. Immunoglobulin gene sequence analysis in chronic lymphocytic leukemia: the 2022 update of the recommendations by ERIC, the European Research Initiative on CLL , 2022, Leukemia.
[3] J. Byrd,et al. Anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia , 2022, Blood advances.
[4] M. Gentile,et al. Unmutated IGHV1-69 CLL Clone Displays a Distinct Gene Expression Profile by a Comparative qRT-PCR Assay , 2022, Biomedicines.
[5] P. Ghia,et al. Are we finally getting personal? Moving towards a personalized approach in chronic lymphocytic leukemia. , 2022, Seminars in cancer biology.
[6] X. Ke,et al. Genetic Landscape of Relapsed and Refractory Diffuse Large B-Cell Lymphoma: A Systemic Review and Association Analysis With Next-Generation Sequencing , 2021, Frontiers in Genetics.
[7] J. Choi,et al. Immunoglobulin Gene Clonality Analysis using Next-Generation Sequencing for Improved Minimal Residual Disease Detection with Significant Prognostic Value in Multiple Myeloma Patients. , 2021, The Journal of molecular diagnostics : JMD.
[8] Marcos González,et al. Liquid biopsy: a non‐invasive approach for Hodgkin lymphoma genotyping , 2021, British journal of haematology.
[9] B. Biderman,et al. Repertoire of Rearranged Immunoglobulin Heavy Chain Genes in Russian Patients With B-Cell Lymphoproliferative Diseases. , 2021, Clinical lymphoma, myeloma & leukemia.
[10] T. Shanafelt,et al. The CLL International Prognostic Index predicts outcomes in monoclonal B-cell lymphocytosis and Rai 0 CLL , 2021, Blood.
[11] Zhi-Nan Xia,et al. IGLL5 is correlated with tumor‐infiltrating immune cells in clear cell renal cell carcinoma , 2021, FEBS open bio.
[12] X. Yao,et al. The Usage of Human IGHJ Genes Follows a Particular Non-random Selection: The Recombination Signal Sequence May Affect the Usage of Human IGHJ Genes , 2020, Frontiers in Genetics.
[13] E. Campo,et al. Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL. , 2020, Blood.
[14] J. Hernández-Rivas,et al. Chronic lymphocytic leukemia patients with IGH translocations are characterized by a distinct genetic landscape with prognostic implications , 2020, International journal of cancer.
[15] J. Byrd,et al. Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study , 2020, Clinical Cancer Research.
[16] K. Stamatopoulos,et al. Tracing CLL-biased stereotyped immunoglobulin gene rearrangements in normal B cell subsets using a high-throughput immunogenetic approach , 2020, Molecular Medicine.
[17] P. Campregher,et al. Distinctive IGHV gene usage and stereotyped receptors in South American patients with chronic lymphocytic leukemia , 2019, Hematological oncology.
[18] J. Bailey,et al. The whole genome landscape of Burkitt lymphoma subtypes. , 2019, Blood.
[19] M. Hallek. Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment , 2019, American journal of hematology.
[20] J. Burger,et al. The importance of B cell receptor isotypes and stereotypes in chronic lymphocytic leukemia , 2018, Leukemia.
[21] E. Campo,et al. Tailored approaches grounded on immunogenetic features for refined prognostication in chronic lymphocytic leukemia , 2018, Haematologica.
[22] J. Byrd,et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. , 2018, Blood.
[23] P. A. Futreal,et al. Clinical implications of cancer gene mutations in patients with chronic lymphocytic leukemia treated with lenalidomide. , 2018, Blood.
[24] R. Fulton,et al. A multiple myeloma-specific capture sequencing platform discovers novel translocations and frequent, risk-associated point mutations in IGLL5 , 2018, Blood Cancer Journal.
[25] I. Vlahavas,et al. Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes , 2017, Clinical Cancer Research.
[26] R. Foà,et al. Immunoglobulin gene rearrangements in Chinese and Italian patients with chronic lymphocytic leukemia. , 2016, Oncotarget.
[27] Andrew W. Greaves,et al. The Dohner fluorescence in situ hybridization prognostic classification of chronic lymphocytic leukaemia (CLL): the CLL Research Consortium experience , 2016, British journal of haematology.
[28] Scott D Boyd,et al. DJ Pairing during VDJ Recombination Shows Positional Biases That Vary among Individuals with Differing IGHD Locus Immunogenotypes , 2016, The Journal of Immunology.
[29] M. Kalos,et al. The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma , 2016, Clinical Cancer Research.
[30] S. Gabriel,et al. Whole-genome sequencing reveals activation-induced cytidine deaminase signatures during indolent chronic lymphocytic leukaemia evolution , 2015, Nature Communications.
[31] Lefteris Angelis,et al. Clinical effect of stereotyped B-cell receptor immunoglobulins in chronic lymphocytic leukaemia: a retrospective multicentre study. , 2014, The Lancet. Haematology.
[32] E. Giné,et al. Genomic complexity and IGHV mutational status are key predictors of outcome of chronic lymphocytic leukemia patients with TP53 disruption , 2014, Haematologica.
[33] J. Hernández-Rivas,et al. Mutation Status and Immunoglobulin Gene Rearrangements in Patients from Northwest and Central Region of Spain with Chronic Lymphocytic Leukemia , 2014, BioMed research international.
[34] Kostas Stamatopoulos,et al. Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies. , 2012, Blood.
[35] D. Rossi,et al. The IGHV1-69/IGHJ3 recombinations of unmutated CLL are distinct from those of normal B cells. , 2012, Blood.
[36] T. Shanafelt,et al. Immunoglobulin diversity gene usage predicts unfavorable outcome in a subset of chronic lymphocytic leukemia patients. , 2008, The Journal of clinical investigation.
[37] Nikolaos Laoutaris,et al. Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: Pathogenetic implications and clinical correlations. , 2006, Blood.
[38] D. Catovsky,et al. The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. , 1994, Leukemia.